Drug Profile


Alternative Names: AMO-02; NP-031112; NP-12; Nypta; Zentylor

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuropharma
  • Developer AMO Pharma; Noscira
  • Class Antidementias; Small molecules; Thiadiazoles
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy; Progressive supranuclear palsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myotonic dystrophy
  • Discontinued Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 25 Sep 2017 Interim adverse events and efficacy data from a phase IIa trial in Myotonic dystrophy released by AMO Pharma
  • 25 Sep 2017 AMO Pharma plans a clinical trial for Myotonic dystrophy (In children, In adolescents) in USA, Canada and United Kingdom in 2017
  • 27 Jul 2017 Tideglusib receives Orphan Drug status for Myotonic dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top